Moderna said that a booster dose of its COVID-19 vaccine appeared to be protective against the fast-spreading Omicron variant in laboratory testing and that the current version of the vaccine would continue to be Moderna's "first line of defense against Omicron." The vaccine maker said the decision to focus on the current vaccine, mRNA-1273, was driven in part by how quickly the recently discovered variant is spreading. The company still plans to develop a vaccine specifically to protect against Omicron, which it hopes to advance into clinical trials early next year. "What we have available right now is 1273," Dr. Paul Burton, Moderna's chief medical officer, said in an interview. "It's highly effective, and it's extremely safe. I think it will protect people through the coming holiday period and through these winter months, when we're going to see the most severe pressure of Omicron." The company said a two-dose course of its vaccine generated low neutralizing antibodies against the Omicron variant, but a 50 microgram booster dose increased neutralizing antibodies against the variant 37 fold. A higher, 100 microgram booster dose of the same vaccine drove antibody levels even higher â€“ more than 80 times pre-boost levels. The data, which has not yet been peer reviewed, tested blood from people who had received the vaccine against a pseudo-virus engineered to resemble the Omicron variant. Omicron, a highly contagious variant first detected last month in southern Africa has raced around the globe and been reported in 89 countries, the World Health Organization said on Saturday. It said the number of Omicron cases is doubling in 1.5 to 3 days in areas with community transmission, but noted that much remains unknown about the variant, including the severity of the illness it causes.